[email protected]   +1 (304) 306-0723

Schizophrenia | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030

$6,500.00$19,500.00

Growth of the Diagnosed prevalence Schizophrenia population will contribute to increasing sales in the therapy market over our forecast period. An estimated annual growth rate of 1.40% in the diagnosed Prevalent Schizophrenia population across the major pharmaceutical markets will contribute to increasing Schizophrenia therapy sales. In 2017, there were approximately XX million diagnosed cases of Schizophrenia in the major markets; we expect the number of cases will exceed XX million in 2030 owing to changes in population demographics and increasing cases of treatment resistant Schizophrenia.
The continuous involvement of second-generation treatments for the Schizophrenia patients will contribute to the the overall growth of the Schizophrenia therapy market and The uptake of the emerging treatments will drive significant sales growth for the Schizophrenia market through 2030.
Clear

Description

Schizophrenia is a chronic neuropsychiatric disorder that has a significant impact on the functioning and quality of life of individuals affected by the disease. At present, there is no cure for schizophrenia, and treatment guidelines recommend a combined approach with pharmacologic agents and psychological interventions for first-episode psychosis, acute exacerbations, and prevention of relapse of psychosis.

Currently available antipsychotics, which are thought to work primarily via modulation of dopamine, largely target positive symptoms. As a result, many patients are left with residual negative and cognitive symptoms. To address these gaps in therapy, new research combined with an increased understanding of the etiology and pathophysiology of schizophrenia is leading to the development of novel agents with the goal of improving schizophrenia management.

Schizophrenia Epidemiology

The reported studies from high-income countries are focused on studies that defines Schizophrenia on the basis of the DSM-5 diagnostic criteria, because they allow a more accurate ascertainment of the diagnosed prevalence and outcomes of Schizophrenia in high-income countries, therefore, we expect diagnosis rate ranging from 65% to 70%.
Almost every individual who is diagnosed with schizophrenia will require medication treatment, usually with an antipsychotic medication. In high income countries, decent number of people with schizophrenia have been identified as receiving healthcare, suggesting more than one-third are suffering from a gap in treatment. Therefore, we hold our treatment cases estimates ranging from 65% to 70% based on the views from KOLs.
Schizophrenia Prevalent Cases - Mellalta Meets 2021
Schizophrenia Prevalent Cases – Mellalta Meets 2021
The treated  patients are further broken down to identify treatment-resistant schizophrenia (TRS) patient pool. TRS has been defined as the persistence of symptoms despite ≥2 trials of antipsychotic medications of adequate dose and duration with documented adherence. TRS occurs in up to ~34% in patients with schizophrenia. Furthermore, 80% to 90% of individuals will experience a relapse at some point in the course of their illness, often related to nonadherence to maintenance therapy. Estimated non-adherence rates in schizophrenia are about 50%, widely ranging from 4% (observed in a study with depot neuroleptic drugs) to 72%.
The United States prevalent population of schizophrenia was ~2.7 million in 2017 that accounted for approximately 51% of the total prevalent population of schizophrenia in the 7MM countries. As per Mellalta Meets analysis, these cases of schizophrenia are expected to reach ~3.1 million by 2030, with a CAGR of 0.93% during the study period [2017-2030].
In 2017, the diagnosed prevalent population of schizophrenia in the United States was ~1.9 million, which might increase to ~2.4 million by 2030.

Schizophrenia Market Forecast

Sales of therapies to treat Schizophrenia in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2017-2030 study period, increasing by an estimated $XX billion during this time. The Schizophrenia therapy market is dominated by established conventional agents (second generation antipsychotics); in 2017, they generated more than 89% (nearly $XX billion) of major-market Schizophrenia sales. The expected approval of the new therapies with various mechanisms (MoA) such as Combination of 5HT2A and sigma2 antagonists, Alpha-2a receptor agonist, Serotonin Inverse Agonist, Dopamine D2-Serotonin 2A receptor antagonists, μ-opioid receptor (MOR) antagonist, Muscarinic receptor agonist, and Cannabinoid receptor CB1 inverse agonists, will mark a significant advancement in Schizophrenia treatment and will pave the way for the new developments in the pipeline. We anticipate total sales from the emerging therapies will reach almost $XX billion in 2030.
TOTAL MARKET SIZE OF SCHIZOPHRENIA IN THE US, JAPAN AND EU5
TOTAL MARKET SIZE OF SCHIZOPHRENIA IN THE US, JAPAN AND EU5
-Mellalta Meets
Currently available antipsychotics, which are thought to work primarily via modulation of dopamine, largely target positive symptoms. As a result, many patients are left with residual negative and cognitive symptoms. To address these gaps in therapy, new research combined with an increased understanding of the etiology and pathophysiology of schizophrenia is leading to the development of novel agents with the goal of improving schizophrenia management.
The Schizophrenia therapy market will experience high growth over the study period, increasing from $XX billion in 2017 to $XX billion in 2030. Greater uptake of the new therapies in the pipeline—will primarily drive this growth.
Conventional therapies (i .e ., first generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs)) will remain entrenched as first-line therapies for most Schizophrenia patients. The merican Psychiatric Association (APA) recommends SGAs as first-line treatment of schizophrenia, excluding clozapine due to its AE profile. SGAs are preferred over FGAs because they are less often associated with extrapyramidal side effects (EPS), although SGAs are more often associated with metabolic AEs (eg, weight gain, hyperlipidemia, and diabetes mellitus). Psychiatrists cite the need for new therapies that improve cognition, are capable of treating negative symptoms, improve treatment-resistant schizophrenia, with improved AE profiles, and improve adherence, we do expect a significant change during our 2017-2030 forecast period .

Report Highlights

  • Schizophrenia Current Market Trends
  • Schizophrenia Current & Forecasted Cases across the G7 Countries
  • Schizophrenia Market Opportunities And Sales Potential for Agents
  • Schizophrenia Patient-based Market Forecast to 2030
  • Schizophrenia Untapped Business Opportunities
  • Schizophrenia Product Positioning Vis-a-vis Competitors’ Products
  • Schizophrenia KOLs Insight

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • Schizophrenia Disease Background
    • Schizophrenia Definition
    • Symptoms
    • Risk Factor
    • Diagnosis
  • Epidemiology Estimated and Forecast to 2030
    • Epidemiology Research Method & Data Sources Used
    • United States
      • Prevalent Cases of Schizophrenia in the United States 2020-2030
      • Diagnosed Cases of Schizophrenia in the United States 2020-2030
    • Germany
      • Prevalent Cases of Schizophrenia in Germany 2020-2030
      • Diagnosed Cases of Schizophrenia in Germany 2020-2030
    • France
      • Prevalent Cases of Schizophrenia in France 2020-2030
      • Diagnosed Cases of Schizophrenia in France 2020-2030
    • Italy
      • Prevalent Cases of Schizophrenia in Italy 2020-2030
      • Diagnosed Cases of Schizophrenia in Italy 2020-2030
    • Spain
      • Prevalent Cases of Schizophrenia in Spain 2020-2030
      • Diagnosed Cases of Schizophrenia in Spain 2020-2030
    • United Kingdom
      • Prevalent Cases of Schizophrenia in UK 2020-2030
      • Diagnosed Cases of Schizophrenia in UK 2020-2030
    • Japan
      • Prevalent Cases of Schizophrenia in Japan 2020-2030
      • Diagnosed Cases of Schizophrenia in Japan 2020-2030
    • Current Unmet Needs in Schizophrenia
    • Current Treatment Paradigm
      • Treatment guidelines for Schizophrenia
    • Current Therapy Chapters
      • Marketed Drugs
        • Head-to-Head Comparison
      • Rexulti (brexpiprazole/OPC-34712): Otsuka America Pharmaceutical/Lundbeck
      • Caplyta (lumateperone/ITI-007): Intra-Cellular Therapies
      • Latuda (lurasidone hydrochloride): Sunovion Pharmaceuticals/ Sumitomo Dainippon Pharma
      • Saphris (asenapine): Merck/AbbVie/Schering-Plough Corporation/Allergan
      • Abilify MyCite (aripiprazole tablets with sensor): Otsuka Pharmaceutical
      • Invega Sustenna (paliperidone palmitate): Janssen Research & Development
      • Vraylar/Reagila (cariprazine): Gedeon Richter/AbbVie
      • Adasuve (loxapine): Alexza Pharmaceuticals
      • Secuado (asenapine/HP-3070): Noven Pharmaceuticals/Hisamitsu Pharmaceutical
      • Invega Trinza: Janssen Pharmaceuticals
      • Aristada and Aristada Initio: Alkermes
      • Perseris (risperidone): Indivior
    • Emerging Therapies Chapters
      • Emerging Drugs
        • Head to Head Comparison
      • Doria (risperidone ISM): Rovi Pharmaceuticals Laboratories
      • Roluperidone (MIN-101): Minerva Neurosciences
      • SEP-363856: Sunovion/PsychoGenics
      • Pimavanserin: Acadia Pharmaceuticals
      • Encenicline (EVP-6124): Forum Pharmaceuticals
      • Dexmedetomidine (BXCL501): BioXcel Therapeutics
      • Avisetron (AVN-211): Avineuro Pharmaceuticals
      • ALKS 3831 (Olanzapine + Samidorphan): Alkermes
      • AVP-786: Avanir Pharmaceuticals/Otsuka Pharmaceutical/Concert Pharmaceuticals
      • Lu AF11167: H. Lundbeck A/S
      • GWP42003 (Cannabidiol/GWP42003-P): GW Research
      • BI 409306: Boehringer Ingelheim
      • KarXT: Karuna Pharmaceuticals
      • TAK-831: Takeda
      • NaBen (Sodium Benzoate): SyneuRx International
      • BI 425809: Boehringer Ingelheim
      • BIIB104 (AMPA): Biogen
      • RO6889450: Roche
      • PF-06412562: Cerevel Therapeutics/Pfizer
      • CTP-692: Concert Pharmaceuticals
      • Evenamide (NW-3509/NW-3509A): Newron Pharmaceuticals
      • Miricorilant: Corcept Therapeutics
      • MK-8189: Merck
      • CPL500036: Celon Pharma
    • KOLs View
    • Total Market Forecast
      • Key Summary Findings
        • G7 total Market for Schizophrenia 2020-2030 (USD Million)
        • G7 total Market for Schizophrenia by Therapies 2020-2030 (USD Million)
      • United States
        • United States Market for Schizophrenia 2020-2030 (USD Million)
        • United States Market for Schizophrenia by Therapies 2020-2030 (USD Million)
      • Germany
        • Germany Market for Schizophrenia 2020-2030 (USD Million)
        • Germany Market for Schizophrenia by Therapies 2020-2030 (USD Million)
      • France
        • France Market for Schizophrenia 2020-2030 (USD Million)
        • France Market for Schizophrenia by Therapies 2020-2030 (USD Million)
      • Italy
        • Italy Market for Schizophrenia 2020-2030 (USD Million)
        • Italy Market for Schizophrenia by Therapies 2020-2030 (USD Million)
      • Spain
        • Spain Market for Schizophrenia 2020-2030 (USD Million)
        • Spain Market for Schizophrenia by Therapies 2020-2030 (USD Million)
      • United Kingdom
        • United Kingdom Market for Schizophrenia 2020-2030 (USD Million)
        • United Kingdom Market for Schizophrenia by Therapies 2020-2030 (USD Million)
      • Japan
        • Japan Market for Schizophrenia 2020-2030 (USD Million)
        • Japan Market for Schizophrenia by Therapies 2020-2030 (USD Million)
      • Reimbursement & Market Access
      • Market Drivers & Barriers
      • Appendix
      • Bibliography
Name
Email
Phone
Enquiry

You may also like…

Get In Touch

Let's keep the conversation going